Jazz Pharmaceuticals stock trades at EUR 185.18 ahead of November 2 results

Published on 10/20/2026 at 12:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue rose 15.5 percent to USD 1.21 billion. Jazz Pharmaceuticals stock costs EUR 185.18 on October 20, 2026 before November 2 results.

Reporting date and operating scale

Jazz Pharmaceuticals announced its third-quarter results date on October 19, 2026.
Second-quarter revenue reached USD 1.21 billion, up 15.5 percent year over year.
Jazz Pharmaceuticals stock traded at EUR 185.18 at 12:37 p.m. CEST at Lang & Schwarz on October 20, 2026.
The company withdrew Zepzelca's second-line indication on September 30, 2026.

JAZZ, IE00B4Q5ZN47, Illustration mit AI erstellt.

Jazz Pharmaceuticals stock (ISIN IE00B4Q5ZN47) was trading at EUR 185.18 at Lang & Schwarz on October 20, 2026 at 12:37 p.m. CEST. The company had announced on October 19, 2026 that it will publish third-quarter 2026 results on November 2 after the U.S. market close, with a webcast at 4:30 p.m. ET, according to Yahoo Finance.

Revenue reached USD 1.21 billion

Jazz reported second-quarter revenue of USD 1.21 billion for the period ended June 30, 2026, up 15.5 percent from USD 1.05 billion a year earlier. Adjusted earnings per share came in at USD 5.71, below the USD 6.18 consensus estimate, while revenue exceeded the USD 1.11 billion expectation, according to MarketBeat. The figures give the November report a clear test: revenue growth must continue while earnings recover against expectations.

What does the pipeline mean?

Jazz's oncology strategy faces a specific regulatory counterweight. On September 30, 2026, the FDA withdrew Zepzelca's accelerated approval for previously treated small-cell lung cancer after the phase 3 LAGOON trial showed median overall survival of 8.7 months with Zepzelca alone versus 10.7 months with chemotherapy, as CURE reported on October 9, 2026. The withdrawal did not affect Zepzelca's maintenance use with Tecentriq.

Three dates shape the stock

On August 3, 2026, Jazz reported USD 1.21 billion in second-quarter revenue and USD 192.8 million in net income, according to Markets Insider. On September 30, 2026, the Zepzelca indication withdrawal involved survival of 8.7 months versus 10.7 months for chemotherapy, according to CURE. On October 19, 2026, Jazz set November 2, 2026 for its third-quarter report, according to Yahoo Finance.

November 2 is the next test

The next dated event is the third-quarter results release on November 2, 2026, followed by management's 4:30 p.m. ET webcast. For investors, the release will show whether the USD 4.60 billion to USD 4.75 billion full-year revenue outlook remains supported by the second-half portfolio.

Stock price and reporting date

Jazz Pharmaceuticals has a USD 13.5 billion market capitalization and a USD 128.80 to USD 266.38 52-week range, based on October 19, 2026 market data. Its primary listing is Nasdaq under ticker JAZZ, and the company operates in the Healthcare and Biotechnology sectors.

Jazz Pharmaceuticals was trading at EUR 185.18 at Lang & Schwarz on October 20, 2026 at 12:37 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Jazz Pharmaceuticals stock.